Search alternatives:
mean decrease » a decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
5 c » 25 c (Expand Search)
Showing 241 - 260 results of 49,944 for search '(( 5 c decrease ) OR ( 5 ((we decrease) OR (((nn decrease) OR (mean decrease)))) ))', query time: 0.83s Refine Results
  1. 241
    TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin.

    TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin. by Martin Selinger (3195987)

    Published 2019
    Save to List
    Saved in:
  2. 242
    Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3.

    Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3. by Martin Selinger (3195987)

    Published 2019
    “…Significant difference from the control was calculated using one-sample Student’s t-test (* P<0.05). (C) Relative quantification of 5S rRNA in CHX-treated DAOY cells (6 and 14 hours post treatment; 100 μg/ml) using the Δ-c<sub>t</sub> method. …”
    Save to List
    Saved in:
  3. 243
    Fig 3 Data.

    Fig 3 Data. by Kevin D. Gaitonde (15411707)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  4. 244
    S2 Fig Data.

    S2 Fig Data. by Kevin D. Gaitonde (15411707)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  5. 245
    Fig 2D–2F Data.

    Fig 2D–2F Data. by Kevin D. Gaitonde (15411707)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  6. 246
    Fig 6 Data.

    Fig 6 Data. by Kevin D. Gaitonde (15411707)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  7. 247
    Fig 1 Data.

    Fig 1 Data. by Kevin D. Gaitonde (15411707)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 248
    Fig 4 Data.

    Fig 4 Data. by Kevin D. Gaitonde (15411707)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  9. 249
    S5 Fig -

    S5 Fig - by Kristen L. Lokken-Toyli (9455263)

    Published 2024
    Save to List
    Saved in:
  10. 250
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 251
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 252
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 253
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 254
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 255
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 256
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 257
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 258
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 259
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 260
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: